Early detection by Grail (leveraging illumina’s gene sequencing technology) looks promising. This truly will be beneficial for early detection. And, I will be very interested in seeing how it benefits those who are genetically pre-disposed to cancer related gene mutations especially around Esaphogus, Glioblastoma, and Pancreatic cancers since these are often hard to detect in their earliest stages.